Special lssues

Advances in Cancer Immunotherapy

Submission Deadline: 22 May 2024 Submit to Special Issue

Guest Editors

Wenxue Ma, University of California, San Diego, USA. E-mail: wma@health.ucsd.edu
Manoj Kumar Kashyap, Amity University Haryana, India. E-mail: mkkashyap@ggn.amity.edu
Lingeng Lu, Yale University, USA. E-mail: lingeng.lu@yale.edu


Cancer immunotherapy has revolutionized cancer treatment by harnessing the power of the immune system to target and eradicate cancer cells. This special issue aims to provide an overview of the recent advances in cancer immunotherapy.


Potential topics include but are not limited to the following:

1. Immunotherapy for solid tumors

2. Biomarkers for immunotherapy response

3. Immune-related adverse events

4. Mechanisms of immune escape


Immunotherapy for solid tumors: This section will discuss the latest updates in immunotherapy for solid tumors, including cytokines, cancer vaccines, immune checkpoint inhibitors, monoclonal antibodies, adoptive cell therapy, etc.


Biomarkers for immunotherapy response: This section will highlight the latest developments in biomarkers for predicting response to immunotherapy and monitoring treatment efficacy.


Immune-related adverse events: This section will cover the management of immune-related adverse events associated with cancer immunotherapy.


Mechanisms of immune escape: This section will discuss the mechanisms by which cancer cells evade the immune system and how to overcome these barriers to enhance the effectiveness of cancer immunotherapy.


This special issue will provide a comprehensive overview of the recent advances in cancer immunotherapy, highlighting the challenges and opportunities for future research in this field.


Immunotherapy, solid tumor, immune checkpoint inhibitors, adoptive cell therapy, and cancer vaccines; Immune-related adverse events, immune escape, immune response, biomarkers

Published Papers

  • Open Access


    Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy

    Oncology Research, Vol.32, No.1, pp. 49-60, 2024, DOI:10.32604/or.2023.042383
    (This article belongs to this Special Issue: Advances in Cancer Immunotherapy)
    Abstract Cancer immunotherapy has emerged as a promising strategy for the treatment of cancer, with the tumor microenvironment (TME) playing a pivotal role in modulating the immune response. CD47, a cell surface protein, has been identified as a crucial regulator of the TME and a potential therapeutic target for cancer therapy. However, the precise functions and implications of CD47 in the TME during immunotherapy for cancer patients remain incompletely understood. This comprehensive review aims to provide an overview of CD47’s multifaced role in TME regulation and immune evasion, elucidating its impact on various types of immunotherapy outcomes, including checkpoint inhibitors and… More >

    Graphic Abstract

    Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy

Share Link